Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAGGER: Staggered Chemo-Immunotherapy for Metastatic Non-Squamous NSCLC
NCT04163432Phase 2Terminated
- Sponsor
- University of Utah
- Start
- Jun 2020
- Primary completion
- May 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of durvalumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by University of Utah. Primary endpoint: Clinical Benefit at 11 months. Started Jun 2020; status: terminated.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04163432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04163432.